CYCC
Cyclacel Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$14.25M
P/E Ratio
0.00
EPS
$7123.50
Beta
0.16
52W High
$87.82
52W Low
$3.08
50-Day MA
$8.11
200-Day MA
$44.19
Dividend Yield
0.00%
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey.
Fundamentals
| Revenue (TTM) | 10,000 |
| Gross Profit (TTM) | 10,000 |
| EBITDA | $-10.36M |
| Operating Margin | -103580.00% |
| Return on Equity | -276.80% |
| Return on Assets | -102.80% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $2.29 |
| Price-to-Book | 3.68 |
| Price-to-Sales (TTM) | 1425.11 |
| EV/Revenue | 907.72 |
| EV/EBITDA | 0.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $2.24M |
| Float | 14,640 |
| % Insiders | 79.47% |
| % Institutions | 0.80% |
More HEALTHCARE Stocks
Data last updated: 5/2/2026